NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

Toll-like receptors (TLRs) play a critical role in innate immune system responses to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). A growing body of evidence suggests that excessive TLR-mediated innate immune system activation can lead to neuronal damage and precipitate or perpetuate neurodegenerative diseases. Among TLR subtypes, both TLR2 and TLR9 have been implicated in neurodegenerative disorders with increased expression of these receptors in the central nervous system being associated with pro-inflammatory signaling and increased burdens of pathologic aggregated proteins. In the current study, we characterized the actions of a combined TLR2/TLR9 antagonist, NPT1220-312, on pro-inflammatory signaling and cytokine release in monocyte/macrophage-derived heterologous cells, human microglia, and murine and human whole blood. NPT1220-312 potently blocked TLR2- and TLR9-mediated release of inflammatory cytokines in monocyte/macrophage cells and in human microglia. NPT1220-312 also blocked TLR2-mediated activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome including IL-1β, IL-18, and apoptosis-associated speck-like protein containing a CARD (ASC) release to the culture medium of human differentiated macrophages. The ability of NPT1220-312 to inhibit TLR2 mediated pro-inflammatory release of chemokines and cytokines in situ was demonstrated using murine and human whole blood. Together, these findings suggest that blockade of TLR2 and TLR9 may reduce inappropriate production of pro-inflammatory cytokines and chemokines from peripheral and central immune cells and thus potentially provide therapeutic benefit in neuroinflammatory/neurodegenerative disorders.

[1]  K. Pahan,et al.  Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo , 2021, Nature Communications.

[2]  Z. Zuo,et al.  Toll‐like receptor 2 activation and up‐regulation by high mobility group box‐1 contribute to post‐operative neuroinflammation and cognitive dysfunction in mice , 2021, Journal of neurochemistry.

[3]  Zhentao Zhang,et al.  Reactive microglia enhance the transmission of exosomal alpha-synuclein via toll-like receptor 2. , 2021, Brain : a journal of neurology.

[4]  E. Masliah,et al.  Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells , 2021, Experimental & Molecular Medicine.

[5]  R. Veerhuis,et al.  α‐Synuclein evokes NLRP3 inflammasome‐mediated IL‐1β secretion from primary human microglia , 2021, Glia.

[6]  B. Hyman,et al.  Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration , 2020, Neurobiology of Disease.

[7]  T. Maiti,et al.  α-Synuclein Exhibits Differential Membrane Perturbation, Nucleation, and TLR2 Binding through Its Secondary Structure. , 2020, ACS chemical neuroscience.

[8]  Q. Tong,et al.  NLRP3 Inflammasome Inhibition Prevents α-Synuclein Pathology by Relieving Autophagy Dysfunction in Chronic MPTP–Treated NLRP3 Knockout Mice , 2020, Molecular Neurobiology.

[9]  M. Heneka,et al.  Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct α-Synuclein Assemblies , 2020, The Journal of Immunology.

[10]  Tyler K. Ulland,et al.  The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease , 2020, Frontiers in Neurology.

[11]  A. Sevilla,et al.  Glia Crosstalk in Neuroinflammatory Diseases , 2020, Frontiers in Cellular Neuroscience.

[12]  J. Choe,et al.  Toll-Like Receptor 9 Is Involved in NLRP3 Inflammasome Activation and IL-1β Production Through Monosodium Urate-Induced Mitochondrial DNA , 2020, Inflammation.

[13]  K. Schroder,et al.  The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins , 2020, Glia.

[14]  Xiao-Min Wang,et al.  Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease , 2020, Journal of Neuroinflammation.

[15]  Qingqing Zhu,et al.  Extracellular mitochondrial DNA promote NLRP3 inflammasome activation and induce acute lung injury through TLR9 and NF-κB. , 2019, Journal of thoracic disease.

[16]  C. Day,et al.  MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition , 2019, Nature Chemical Biology.

[17]  B. Beutler,et al.  Excessive endosomal TLR signaling causes inflammatory disease in mice with defective SMCR8-WDR41-C9ORF72 complex function , 2018, Proceedings of the National Academy of Sciences.

[18]  K. Schroder,et al.  Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice , 2018, Science Translational Medicine.

[19]  E. Masliah,et al.  Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation , 2018, Molecular Neurodegeneration.

[20]  R. Ransohoff,et al.  TLR9 activation via microglial glucocorticoid receptors contributes to degeneration of midbrain dopamine neurons , 2018, Nature Communications.

[21]  G. Forloni,et al.  Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2 , 2018, Brain, Behavior, and Immunity.

[22]  B. Barres,et al.  Microglia and macrophages in brain homeostasis and disease , 2017, Nature Reviews Immunology.

[23]  G. Halliday,et al.  Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology , 2016, Acta Neuropathologica.

[24]  M. Lynch,et al.  Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease , 2016, Brain, Behavior, and Immunity.

[25]  B. Czerniecki,et al.  Insights into Soluble Toll-Like Receptor 2 as a Downregulator of Virally Induced Inflammation , 2016, Front. Immunol..

[26]  E. Masliah,et al.  Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2 , 2016, Experimental neurobiology.

[27]  D. Underhill,et al.  C9orf72 is required for proper macrophage and microglial function in mice , 2016, Science.

[28]  S. Lehnardt,et al.  Microglia Induce Neurotoxic IL-17+ γδ T Cells Dependent on TLR2, TLR4, and TLR9 Activation , 2015, PloS one.

[29]  M. Lynch,et al.  α-TLR2 antibody attenuates the Aβ-mediated inflammatory response in microglia through enhanced expression of SIGIRR , 2015, Brain, Behavior, and Immunity.

[30]  Michelle H. W. Laird,et al.  Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain , 2015, Proceedings of the National Academy of Sciences.

[31]  Martyn F. Symmons,et al.  Assembly and localization of Toll-like receptor signalling complexes , 2014, Nature Reviews Immunology.

[32]  Melvin J. Yu,et al.  Novel Small Molecule Inhibitors of TLR7 and TLR9: Mechanism of Action and Efficacy In Vivo , 2014, Molecular Pharmacology.

[33]  J. George,et al.  VB‐201, an oxidized phospholipid small molecule, inhibits CD14‐ and Toll‐like receptor‐2‐dependent innate cell activation and constrains atherosclerosis , 2014, Clinical and experimental immunology.

[34]  E. Park,et al.  Knockout of Toll-like receptor 2 attenuates Aβ25–35-induced neurotoxicity in organotypic hippocampal slice cultures , 2013, Neurochemistry International.

[35]  W. Hait,et al.  Therapeutic Targeting of Autophagy in Disease: Biology and Pharmacology , 2013, Pharmacological Reviews.

[36]  E. Masliah,et al.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.

[37]  DelindaA . Johnson,et al.  Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein , 2012, Journal of Neuroimmune Pharmacology.

[38]  Huan Yang,et al.  Expression of Toll-Like Receptors 2, 4 and 9 in Patients with Guillain-Barré Syndrome , 2011, Neuroimmunomodulation.

[39]  U. Švajger,et al.  Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines , 2011, The Journal of Immunology.

[40]  E. Aronica,et al.  Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue , 2011, Neuroscience.

[41]  E. Hirsch,et al.  Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism , 2011, Proceedings of the National Academy of Sciences.

[42]  D. Knipe,et al.  Discovery of a novel TLR2 signaling inhibitor with anti-viral activity. , 2010, Antiviral research.

[43]  T. Mogensen.  Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses , 2009, Clinical Microbiology Reviews.

[44]  M. Onofrj,et al.  Peripheral cytokines profile in Parkinson’s disease , 2009, Brain, Behavior, and Immunity.

[45]  K. Moore,et al.  The NALP3 inflammasome is involved in the innate immune response to amyloid-β , 2008, Nature Immunology.

[46]  T. Kenakin,et al.  Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists , 2006, Journal of Pharmacology and Experimental Therapeutics.

[47]  Harald Neumann,et al.  Neuronal injury mediated via stimulation of microglial toll‐like receptor‐9 (TLR9) , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[49]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[50]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.